Macrophage depletion by free bisphosphonates and Zoledronate-loaded red blood cells

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Sabatino, Raffaella ^a   Antonelli, Antonella ^a   Battistelli, Serafina ^a   Schwendener, Reto ^b   Magnani, Mauro ^a,c   Rossi, Luigia ^a,c  

^a UNIVERSITY OF URBINO   (Italy)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c EryDel SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL ENCAPSULATION; CELL ENGINEERING; CELL KILLING; CONCENTRATION RESPONSE; DOSE RESPONSE; DRUG DELIVERY SYSTEM; ERYTHROCYTE CONCENTRATE; FEMALE; HUMAN; HUMAN CELL; HUMAN VERSUS ANIMAL COMPARISON; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; MACROPHAGE; MOUSE; NONHUMAN; SPLEEN CELL; ANIMAL; CELL CULTURE; CHEMISTRY; DRUG EFFECTS; ERYTHROCYTE; LIVER; METABOLISM; SPLEEN;

ANIMALS; CELL ADHESION; CELLS, CULTURED; DIPHOSPHONATES; ERYTHROCYTES; HUMANS; IMIDAZOLES; LIVER; MACROPHAGES; MICE; PROTEIN BINDING; SPLEEN;

EID: 84903392007     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101260     Document Type: Article

References (66)

1. Stasi R (2012) Immune thrombocytopenia: pathophysiologic and clinical update. Semin Thromb Hemost 38(5): 454-62.
2. Oldenborg PA (2004) Role of CD47 in erythroid cells and in autoimmunity. Leuk Lymphoma 45(7): 1319-27.
3. Meltzer MS, Skillman DR, Gomatos PJ, Kalter DC, Gendelman HE (1990) Role of mononuclear phagocytes in the pathogenesis of human immunodeficiency virus infection. Annu Rev Immunol 8: 169-94. (Pubitemid 20135625)
4. Wu L, Morahan PS, Hendrzak JA, Eisenstein TK (1994) Herpes simplex virus type 1 replication and IL-1 beta gene expression in mouse peritoneal macrophages activated in vivo by an attenuated Salmonella typhimurium vaccine or Corynebacterium parvum. Microb Pathog 16(6): 387-99.
5. Ruiz P, Maldonado P, Hidalgo Y, Gleisner A, Sauma D, et al. (2013) Transplant tolerance: new insights and strategies for long-term allograft acceptance. Clin Dev Immunol 2013: 210506.
6. van Nieuwenhuijze A, Koenders M, Roeleveld D, Sleeman MA, van den Berg W, et al. (2013) GM-CSF as a therapeutic target in inflammatory diseases. Mol Immunol 56(4): 675-82.
7. Jedynak M, Siemia̧tkowski A, Rygasiewicz K (2012) Molecular basics of sepsis developement. Anaesthesiol Intensive Ther 44(4): 221-5.
8. Mantovani A, Marchesi F, Porta C, Sica A, Allavena P (2007) Inflammation and cancer. Breast cancer as prototype. The Breast 16(2): 27-33.
9. Shih J-Y, Yuan A, Chen JJ-W, Yang P-C (2006) Tumor-Associated Macrophage: Its Role in Cancer Invasion and Metastasis. J Cancer Molec 2(3): 101-106.
10. Solinas G, Germano G, Mantovani A, Allavena P (2009) Tumor-associated macrophages (TAM) as major players of cancer-related inflammation. J Leuk Biol 86(5): 1065-1073.
11. Moreau MF, Guillet C, Massin P, Chevalier S, Gascan H, et al. (2007) Comparative effects of five bisphosphonates on apoptosis of macrophage cells in vitro. Biochem Pharmacol 73(5): 718-23. (Pubitemid 46172458)
12. Frith JC, Rogers MJ (2003) Antagonistic effects of different classes of bisphosphonates in osteoclasts and macrophages in vitro. J Bone Miner Res 18(2): 204-12. (Pubitemid 36125912)
13. Selander KS, Mönkkönen J, Karhukorpi EK, Härkönen P, Hannuniemi R, et al. (1996) Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 50(5): 1127-38. (Pubitemid 26384851)
14. Rogers MJ, Chilton KM, Coxon FP, Lawry J, Smith MO, et al. (1996) Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 11(10): 1482-91. (Pubitemid 26331003)
15. Mönkkönen H, Rogers MJ, Makkonen N, Niva S, Auriola S, et al. (2001) The cellular uptake and metabolism of clodronate in RAW 264 macrophages. Pharm Res 18(11): 1550-5. (Pubitemid 33022410)
16. Cecchini MG, Felix R, Fleisch H, Cooper PH (1987) Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res 2(2): 135-42.
17. Valleala H, Hanemaaijer R, Mandelin J, Salminen A, Teronen O, et al. (2003) Regulation of MMP-9 (gelatinase B) in activated human monocyte/macrophages by two different types of bisphosphonates. Life Sci 73(19): 2413-20. (Pubitemid 37107352)
18. Melani C, Sangaletti S, Barazzetta FM, Werb Z, Colombo MP (2007) Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 67(23): 11438-46. (Pubitemid 350248572)
19. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, et al. (2010) Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 14(12): 2803-15.
20. Giraudo E, Inoue M, Hanahan D (2004) An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 114(5): 623-33. (Pubitemid 39578752)
21. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, et al. (2010) Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br J Cancer 103(5): 629-41.
22. Zhang W, Zhu XD, Sun HC, Xiong YQ, Zhuang PY, et al. (2010) Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 16(13): 3420-30.
23. Katzav A, Bina H, Aronovich R, Chapman J (2013) Treatment for experimental autoimmune neuritis with clodronate (Bonefos). Immunol Res 56(2-3): 334-40.
24. Strobach D, Lorenz RL (2003) The bisphosphonate ibandronate stimulates reverse cholesterol transport out of monocytoid cells by enhanced ABCA1 transcription. Biochem Biophys Res Commun 307(1): 23-30. (Pubitemid 36808531)
25. Matsuo A, Shuto T, Hirata G, Satoh H, Matsumoto Y, et al. (2003) Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis. J Rheumatol 30(6): 1280-90. (Pubitemid 36666355)
26. Ylitalo R, Syvälä H, Tuohimaa P, Ylitalo P (2002) Suppression of immunoreactive macrophages in atheromatous lesions of rabbits by clodronate. Pharmacol Toxicol 90(3): 139-43. (Pubitemid 34289611)
27. Takayama J, Koyamada N, Abe T, Hatsugai K, Usuda M, et al. (2000) Macrophage depletion prevents accelerated rejection and results in long-term survival in hamster to rat cardiac xenotransplantation. Transplant Proc 32(5): 1016. (Pubitemid 30601855)
28. Bottino R, Fernandez L, Ricordi C, Oliver R, Lehmann R, et al. (1997) Transient macrophage inactivation decreases the occurrence of early graft loss in rodents. Transplant Proc 29(4): 2057. (Pubitemid 27265228)
29. Mebius RE, Bauer J, Twisk AJ, Brevé J, Kraal G (1991) The functional activity of high endothelial venules: a role for the subcapsular sinus macrophages in the lymph node. Immunobiology 182(3-4): 277-91.
30. Rodan GA, Reszka AA (2002) Bisphosphonate mechanism of action. Curr Mol Med 2(6): 571-577. (Pubitemid 34982189)
31. Chapurlat RD, Laroche M, Thomas T, Rouanet S, Delmas PD, et al. (2013) Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial. Osteoporos Int 24(1): 311-20.
32. Fan T, Zhang Q, Sen SS (2013) Persistence with weekly and monthly bisphosphonates among postmenopausal women: analysis of a US pharmacy claims administrative database. Clinicoecon Outcomes Res 5: 589-95.
33. Crowley R, Gittoes N (2013) How to approach hypercalcaemia. Clin Med 13(3): 287-90.
34. Reid IR (2012) Pharmacotherapy of Paget's disease of bone. Expert Opin Pharmacother 13(5): 637-46.
35. Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M (2012) Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 25(5-6): 485-91.
36. Young RJ, Coleman RE (2013) Zoledronic acid to prevent and treat cancer metastasis: new prospects for an old drug. Future Oncol 9(5): 633-43.
37. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, et al. (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18): 1809-22. (Pubitemid 46698462)
38. Cummings SR, Schwartz AV, Black DM (2007) Alendronate and atrial fibrillation. N Engl J Med 356: 1895-1896.
39. Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, et al. (2007) Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357(18): 1799-809. (Pubitemid 350044800)
40. Reid IR (2009) Osteonecrosis of the jaw: who gets it and why? Bone 44: 4-10.
41. Abrahamsen B (2010) Adverse effects of bisphosphonates. Calcif Tissue Int 86: 421-435.
42. van Rooijen N, van Kesteren-Hendrikx E (2002) Clodronate liposomes: perspectives in research and therapeutics. J Liposome Res 12(1-2): 81-94.
43. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjällman AH, Ballmer-Hofer K, et al. (2006) Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. Br J Cancer 95(3): 272-81. (Pubitemid 44187587)
44. Hafeman S, London C, Elmslie R, Dow S (2010) Evaluation of liposomal clodronate for treatment of malignant histiocytosis in dogs. Cancer Immunol Immunother 59(3): 441-52.
45. Bonabello A, Galmozzi MR, Canaparo R, Serpe L, Zara GP (2003) Long-term analgesic effect of clodronate in rodents. Bone 33(4): 567-74. (Pubitemid 37222383)
46. Alves-Rosa F, Stanganelli C, Cabrera J, van Rooijen N, Palermo MS, et al. (2000) Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood 96(8): 2834-40.
47. Jordan MB, van Rooijen N, Izui S, Kappler J, Marrack P (2003) Liposomal clodronate as a novel agent for treating autoimmune hemolytic anemia in a mouse model. Blood 101(2): 594-601. (Pubitemid 36077582)
48. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, et al. (2013) Liposome: classification, preparation, and applications. Nanoscale Res Lett 8(1): 102.
49. Shmeeda H, Amitay Y, Tzemach D, Gorin J, Gabizon A (2013) Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity. J Control Release 167(3): 265-75.
50. Millán CG, Marinero ML, Castañeda AZ, Lanao JM (2004) Drug, enzyme and peptide delivery using erythrocytes as carriers. J Control Release 95(1): 27-49. (Pubitemid 38167677)
51. Hamidi M, Zarrin A, Foroozesh M, Mohammadi-Samani S (2007) Applications of carrier erythrocytes in delivery of biopharmaceuticals. J Control Release 118(2): 145-60. (Pubitemid 46329734)
52. Muzykantov VR (2010) Drug delivery by red blood cells: vascular carriers designed by mother nature. Expert Opin Drug Deliv 7(4): 403-27.
53. Magnani M, Serafini S, Fraternale A, Antonelli A, Biagiotti S, et al. (2011) Red Blood Cell-Based Delivery of Drugs and Nanomaterials for Therapeutic and Diagnostic Applications. In: Encyclopedia of Nanoscience and Nanotechnology (Volume 22), Nalwa SH (Ed.), American Scientific Publishers. 309-354.
54. Magnani M, Pierigè F, Rossi L (2012) Erythrocytes as a novel delivery vehicle for biologics: from enzymes to nucleic acid-based therapeutics. Ther Deliv 3(3): 405-14.
55. Kolesnikova TA, Skirtach AG, Möhwald H (2013) Red blood cells and polyelectrolyte multilayer capsules: natural carriers versus polymer-based drug delivery vehicles. Expert Opin Drug Deliv 10(1): 47-58.
56. Magnani M, Chiarantini L, Vittoria E, Mancini U, Rossi L, et al. (1992) Red blood cells as an antigen-delivery system. Biotechnol Appl Biochem 16(2): 188-94.
57. Rossi L, Serafini S, Antonelli A, Pierigé F, Carnevali A, et al. (2005) Macrophage depletion induced by clodronate-loaded erythrocytes. J Drug Target 13(2): 99-111. (Pubitemid 40542542)
58. Shi G, Mukthavaram R, Kesari S, Simberg D (2014) Distearoyl anchor-painted erythrocytes with prolonged ligand retention and circulation properties in vivo. Adv Healthc Mater 3(1): 142-8.
59. Mukthavaram R, Shi G, Kesari S, Simberg D (2014) Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes. J Control Release 183: 146-53.
60. Serafini S, Fraternale A, Rossi L, Casabianca A, Antonelli A, et al. (2009) Effect of macrophage depletion on viral DNA rebound following antiretroviral therapy in a murine model of AIDS (MAIDS). Antiviral Res 81(2): 93-102.
61. Rossi L, Migliavacca B, Pierigé F, Serafini S, Sanvito F, et al. (2008) Prolonged islet allograft survival in diabetic mice upon macrophage depletion by clodronate-loaded erythrocytes. Transplantation 85(4): 648-50.
62. Magnani M, Rossi L, Brandi G, Schiavano GF, Montroni M, et al. (1992) Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: In vitro and in vivo studies. Proc Natl Acad Sci 89: 6477-6481.
63. Lutz HU (2012) Naturally occurring autoantibodies in mediating clearance of senescent red blood cells. Adv Exp Med Biol 750: 76-90.
64. Veldboer K, Vielhaber T, Ahrens H, Hardes J, Streitbürger A, et al. (2011) Determination of zoledronic acid in human urine and blood plasma using liquid chromatography/electrospray mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 879(22): 2073-2080.
65. Van Rooijen N (1992) Liposome-mediated elimination of macrophages. Research in immunology 143: 215-219.
66. Spencer A, Roberts A, Kennedy N, Ravera C, Cremers S, et al. (2008) Renal safety of zoledronic acid with thalidomide in patients with myeloma: a pharmacokinetic and safety sub-study. BMC Clin Pharmacol 8: 2.